Summary: A simple procedure is described for the detection of sialic acid in serum. After a direct addition of Ehrlich reagent to serum and an incubation at 56 °C for eight hours, the resulting mixture is diluted with saline. After centrifugation, the color in the supernatant is determined at 525 nm in a spectrophotometer. Serum sialic acid was significantly greater in cancer patients than in normals. Cancer patients with metastases had significantly greater sialic acid than cancer patients without metastases. In two cancer patients, sialic acid levels returned to normal after surgery. The diagnostic usefulness of 95.6% was similar to that reported with lipid-soluble sialic acid and seemed to be superior to CEA and other tumor antigens associated with a limited spectrum of tumors. However, patients with inflammatory diseases such äs arthritis, Crohn's disease and psoriasis also showed elevated sialic acid levels.
Introduction (3) (4) (5) (6) .'Serum sialyltransferase and 5'-nucleotidase Several glycosyltransferase levels have been reportwere found to be reliable biomarkers of breast ed to be abnormal in human cancer (l, 2). The cata^ cancer activity, and serial measurements of these enlytic concentrations of one enzyme, sialyltransferase zyme activities were used for the monitoring of diswere found to be elevated in sera obtained for both ease activity and success or failure of the treatment 648 Shambergcr: Serum sialic acid in normals and in cancer patients (7) . Serum sialic acid and sialyltransferase have also been used to monitor tumor b rden in malignant melanoma patients (8) , but sialic acid levels appeared to more closely reflect tumor b rden than sialyltransferase activity. Lipid-bound sialic acid and sialic acid have also been observed to be significantly elevated in cancer patients (9) . In other studies, lipid-bound sialic acid was also found to be elevated in cancer patients (10, 11) .
The methods associated with sialyltransferase measurement, lipid associated sialic acid, and sialic acid are somewhat complex for clinical laboratories. The objective of these experiments is to try to find a less complex way to measure serum sialic acid. In these experiments, Ehrliches reagent is added directly to serum and after a long incubation, the mixture is diluted, centrifuged, and read directly on a spectrophotometer. This method was used to measure sialic acid in the sera of patients with cancer and other diseases.
Material and Method
Sera studied
Siaiic acid level was measured in the sera from 134 normal males and females and 160 cancer patients of which 63 had known metastases. All cancer patients were verified by a biopsy, or pathological examination of their cancer after surgery. The following are the types of cancers and number of patients studied: breast (11); rectal (14) ; uterine (23); leukemias and lymphomas (21); pancreatic (4); lung (14) ; larynx (9); colon (8); ovarian (5); testis (3); Hodgkitfs disease (4); renal (3); bladder (3); esophageal (4); melanoma (7); prostate (4); and 23 patients with several other types of cancer; (4) with sarcomas, and cancer, and (5) with brain tumors. Sialic acid level was also measured in several patients with various types of inflammatory disease: arthritis (42), psoriasis (14) CIO/I/I's disease (13) , and ulcer (3).
Sialic Acid Assay
Water (0.5 ml) was added to 0.5 ml serum. Blank tubes contained l ml of water. At that time, 0.2 ml of Ehrlich solution was added and the solution was vortexed. Ehrliches reagent is made by adding 0.7 g of/7-dimethylaminobenzaldehyde to 150 ml of concentrated HC1 and 100ml of distilled water. Ehrlich'* reagent has been previously used to measure sialic acid (12) .
A white precipitate forms immediately. The tube was covered with parafilm and its Contents were then incubated in a 56 °C water bath for 8 hours. The tubes were agitated gently at l, 3, 5 and 7 hours. The Contents of the tubes gradually turned blue in the eight hour incubation period. At the conclusion of the incubation, 3.0 ml of 9 g/l NaCl solution are added to each tube and they were centrifuged at 2500g for 15 minutes. The supernatant was removed but sometimes contained some precipitate because of mixing during supernatant removal. The supernatant was recentrifuged at 2500g for 15 minutes and then placed in a cuvet, which was read in a Pye-Unicam spectrophotometer at 525 nm. The color was quite stable and could be read 16 hours later with no substantial difference in the absorbance. In two recovery studies in which 5 and 10 μιποί were added to 1.8 μιηοΐ in l ml of serum, the amounts recovered were 6.7 μπιοί (98.5%) and 11.5 μηιοί (97.5%). Although there is no established reference method for sialic acid, one serum was run ten times by this method and the periodate oxidation-thiobarbituric acid-cyclohexanone method (8) . The results by this method wcrc 1.90 ± 0.13 and 1.85 ±0.15 mmol/1 by the other method. Ehrfich's reagent is also known to react with urobilinogen, but this complex has an absorption maximum at 562 nm. The good recovery experienced seems to indicate that the method is sufficiently specific.
The assay was at least linear to an absorbance of 0.630 corresponding to 0.59 mmol/l serum. The serum could be diluted l :2 or l :4 with proportional changes in the bsorbance. Grossly hemolyzed samples, icteric samples, and lipemic samples changed appearance during the long incubation. After the incubation and centrifugation, the supernatant from lipemic and icteric samples could not be visually identified among the other samples. Grossly hemolyzed samples, after incubation, appeared to have a browner precipitate, but had no visible difference in the supernatant. Chemistry control serum 1-Highland Q-pak was used s a quality control sample. This quality control sample was run 42 times on a day-to-day basis and in another experirnerit, 25 samples were run. CEA (Hoffmann LaRoche) levels were compared to sialic acid levels in 10 cancer patients and in two normals.
Sialic acid levels were recorded before and for four days after surgery in a 47-year-oId ferriale with breast cancer and in a 57-year-old male with colon cancer. After searching the medical fecords it was observed that 53 patients had died from cancer or cancer-related complications. To test whether sialic acid levels might be related to the severity of the disease, sialic acid levels were compared to the time of death in these patients. In another experiment to determine the amount of free and bound sialic acid in serum, serum was passed through an Amicon filter Centriflo Ultrafiltration Membrane Cones, CF-50A which is routifiely used to measure ultrafilterable calcium. Sialic acid levels wefe determined on the filtrate.
Results
With the method described above, there was gradual increase of color until the seventh hour of incubation when the increase of absorbance seemed to plateau ( fig. 1 ). In contrast, stan^ajd sialic acid reached rhaximum color action in 45 minutes. Apparently sialic acid was gradually released from some macrom olecule in the serum. Ultrafiltration showed that almost all of the sialic acid was retained on the filter indicating that sialic acid was bound to a rhacrom lecule such s glycoprotein.
Patients with breast, rectal, uterine, pancreatic, lung, laryngeal, colon, ovarian, testicular, bladder, esophageal, and prostatic cancer s well s patients with melanoma, Hodgkin's disease and leukemia or lymphoma had significantly greater sialic acid levels (P < 0.001) than the controls (tab. 1). Of the 160 cancer patients in table l, 151 (94%) had sialic acid levels greater than 2 Standard deviations (S.D.) of the controls. Of the 9 patients wh did not have sialic acid values greater than the controls, one patient with uterine cancer and one with rectal cancer had received radiation treatment either the same day or the day before blood was drawn. In addition, 4 of 4 sarcoma patients had elevated sialic acid levels. The 'results were: bone sarcoma 2.6,.2/2; and leiomysarcoma 2.6, 2/2. Brozmanova &tSkrovina (13) One hundred and thirty-four normals had a serum sialic acid level of 1.74 ± 0.24 (S.D.) mmol/l whereas 160 cancer patients had a level of 2.99 ± 0.72 and 63 cancer patients with inetastases had a level of 3.23 ± 0.73. Using a Mest of significance both the cancer patients and cancer patients with metastases wefe significantly different than the controls (P < 0.001). With the t test, the sialic acid level in cancer patients without metastases was also significantly different thaii the cancer patients with metastases. The higher sialic aicid levels in the patients with metastases probably represents the greater tumor b rden and sialic acid production by the cancer patients. Figure 2 shows the fiVe day postoperative sialic acid levels in a 52-year-old man with colon cancer and a 43-year-old woman with breast cancer. After the cancer was removed the serum sialic acid levels returned to normal. Mrochek et al. (14) have measured protcin-bound sialic acid levels in women with breast cancer. They report consistent increases in those with progressive tumor and consistent decreases in levels in patients whose disease is responding to therapy.
A correlation coefficient of 0.44 (P < 0.01) was observed between sialic acid levels and days before death for 53 cancer patients ( fig. 3 ), which indicates a relationship between sialic acid levels and severity of the disease. Even though one cannot predict the time of death for an individual patient, a greatly elevated sialic acid is a poor prognostic sign. Patients (tab. 2) with inflammatory diseases such äs arthritis (P < 0.001), psoriasis (P < 0.01), Crohn's disease and with ulcers (P < 0.001) also had significantly elevated sialic acid levels.
When the diagnostic usefulness of CEA was compared to sialic acid in two normals and ten cancer patients, (tab. 3), only four of ten patients had an elevated CEA. In contrast, all 10 cancer patients had an elevated sialic acid level. Hyland reference serum (Chemistry Control Serum I Hyland Q-Pak) seemed to be useful äs a quality control serum for sialic acid with a day-to-day (N = 42) coefficient of Variation of 11.6% and within run Variation (N = 25) of 8.4%. 
DSscussion
Methods associated with sialyltransferase measurement, lipid-associated sialic acid, and sialic acid measurement are difficult for routine analysis by clinical laboratories because eithertadioactive^labetted Substrates, labile reagents, or solvent extractions afe required. Sialyltransferase assay requires a precipitation of a radioactive Substrate by phosphötungstic acid precipitation; sialic acid is oxidized with periodic acid and then extracted into cyclohexanone. The major advantages of the procedure reported here is that one stable reagent is added to serum and after incubation in a water bath and centrifugations, the absorbance is read in a spectrophotometer. All of this type of equipmerit is pfesent in a clinical laboratory. The major disadvantage is the 8-hour. incubation plus another hour for final analysis. In addition, the method is known to be less sensitive than the thiobarbituric method (14) . However, the sensitivity of the method was more than adequate. If microcuvettes were used considerably less than 0.5 ml of serurn could be used.
Previous studies have iridicated that lipid-boünd sialic acid may be a reliable marker in cancer (15) . Of 670 cancer patients, 88% had elevated levels compared with 17% of patients witll· benigft disease and no normal patients had elevated levels. In another study (8) , sialic acid levels correlated with cancer diagnosis in 19 of 24 (79%) patients, whereas sialyltransferase indicated cancer in 14 of the 24 patients (58%). Changes in sialyltransferase tended to be less marked than sialic acid and the interassay Variation of the enzyme assay decreased the significance of small changes. The diagnostic usefulness of sialic acid in this study was quite comparable, with 94% (151 of 160) of cancer patients showing elevated levels. There were 4.5% (6 of 134) false-positives. A comparative study between plasma lipid-bound sialic acid levels and CEA showed that 97/125 (78%) cancer patients had elevated lipid-soluble sialic acid (10), but of the satne patients only 44/125 (35%) had elevated CEA. These numbers are comparable to the results of this small series of 100% and 40%. Hogan-Ryan (16) has also observed a higher diagnostic efficiency of sialic acid (56%) in breast cancer patients than CEA (35%). The elevations of serum sialic acid in arthritics were similar to those reported by Silver et al. (8) , who observed significant elevations of sialic acid and sialyltransferase in patients with rheumatoid arthritis. There was a tendency for both markers to be more elevated in patients with active arthritis than in patients with inactive arthritis. The elevations of serum sialic acid may be related to increases of acute phase reactants. In other studies, sialic acid levels correlated with the stage of disease (17) (18) (19) (20) , tumor bürden (8,21)> degree of metastasis (20, 22) , and recurrence of disease (20) . The rapid postoperative decrease of sialic acid ( fig. 2 ) is in contrast to two other studies (23, 24) . Differences in sialic acid determination or types of cancer patients studied may be responsible for these contrasting studies. Unlike tumor antigens, which are associated with a limited spectrum of tumors, increased sialic acid levels due to sialyltransferase activity and associated sialylglycoprotein production appear to be a common phenomenon of a variety of neoplastic cells. As a result, relatively nonspecific markers such äs sialic acid and sialyltransferase or lipid-soluble sialic acid may have useful clinical applications äs a cancer screen. The diagnostic effectiveness of sialic acid is better than that of CEA, one of the leading cancer screening tests. However, because of the technical problems involved in measuring sialic acid, sialyltransferase or lipid-soluble sialic acid, these assays have not been used widely. This simplified assay should enhance acceptance of the test. Even though there are false positives with arthritics and in patients with other inflammatory diseases, measurement of sialic acid is, however, dramatically easier than measurement of other cancer markers. In addition, 5-10% of false positives of normal patients also occur with CEA (21, 25) . Other types of tests could be done in conjunction with an elevated sialic acid level to help with its diagnostic effectiveness.
